# A Study of PER-001 in Participants With Open-Angle Glaucoma

> **NCT05822245** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Perfuse Therapeutics, Inc.** · enrollment: 36 (estimated)

## Conditions studied

- Open-angle Glaucoma

## Interventions

- **DRUG:** PER-001 Intravitreal Implant - Low Dose
- **DRUG:** PER-001 Intravitreal Implant - High Dose
- **DRUG:** PER-001 Intravitreal Implant - Sham

## Key facts

- **NCT ID:** NCT05822245
- **Lead sponsor:** Perfuse Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-05-25
- **Primary completion:** 2025-04-04
- **Final completion:** 2026-04-04
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05822245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05822245, "A Study of PER-001 in Participants With Open-Angle Glaucoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05822245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*